middle.news
Hydrix Advances with FDA Milestone and Narrows Q3 Losses Amid Cash Challenges
4:44am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Hydrix Advances with FDA Milestone and Narrows Q3 Losses Amid Cash Challenges
4:44am on Monday 2nd of June, 2025 AEST
Key Points
Group cash operating loss halved to $0.75m in Q3 FY25
Gyder Surgical Hip Navigation system achieves FDA 510(k) clearance, triggering equity uplift
Services segment revenue slightly declined to $2.1m but holds $40m in potential future projects
Cash on hand at $0.3m supported by a $2m Letter of Comfort from a major shareholder
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Hydrix (ASX:HYD)
OPEN ARTICLE